Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
- Conditions
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 366
- Registration Number
- NCT00266747
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Enoxaparin in Acute Venous Thromboembolic Disease
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 251
- Registration Number
- NCT00265993
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Irbesartan in Hypertension
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 88
- Registration Number
- NCT00265967
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
TEDDY: Spores of Bacillus Clausii in Acute Diarrhoea in Children
- Conditions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 420
- Registration Number
- NCT00265369
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
- Conditions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT00264914
- Locations
- 🇨🇦
sanofi-aventis Canada, Laval, Canada
🇨🇭Sanofi-Aventis Administrative Office, Geneva, Switzerland
Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
- Conditions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2008-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 77
- Registration Number
- NCT00264927
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
AMISH : Aprovel for Management of Isolated Systolic Hypertension
- Conditions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 436
- Registration Number
- NCT00264212
- Locations
- 🇹🇭
Sanofi-Aventis, Bangkok, Thailand
VALID : VAlproate Versus LIthium in Bipolar Disorders
- Conditions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 270
- Registration Number
- NCT00264173
Oxaliplatin in Gastric Cancer
- Conditions
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2010-11-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT00263354
Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT00263029